Research programme: xerostomia therapy - Medpharma/Straumann

Drug Profile

Research programme: xerostomia therapy - Medpharma/Straumann

Alternative Names: Xerostomia research programme - Medpharma/Straumann

Latest Information Update: 05 May 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Institut Straumann
  • Class
  • Mechanism of Action Acetylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Xerostomia

Most Recent Events

  • 05 May 2008 Discontinued - Phase-I for Xerostomia in Sweden (unspecified route)
  • 24 Aug 2004 Biora has been acquired by, and merged into, Institut Straumann
  • 19 Apr 2001 Phase-I clinical trials for Xerostomia in Sweden (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top